Osimertinib AZD9291, 1421373-65-0 , 99.5%
TAGRISSO™ (AZD9291) approved by the US FDA for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer.
EOS Med Chem, finish it in 2015, Nov. EE is 99.5%.
| Osimertinib AZD9291 | |||
| Int 1 | N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide | 1421373-65-0 | ＞99.5 |
| Int 2 | N1-[2-(Dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]-2-nitro-1,4-benzenediamine | 1421372-67-9 | ＞98% |
| Int 3 | N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinamine | 1421372-94-2 | ＞98% |
| Int 4 | 3-(2-Chloro-4-pyrimidinyl)-1-methyl-1H-indole | 1032452-86-0 | ＞98% |
